Bain Capital Life Sciences Investors 13F annual report
Bain Capital Life Sciences Investors is an investment fund managing more than $910 billion ran by Adam Koppel. There are currently 24 companies in Mr. Koppel’s portfolio. The largest investments include Nuvalent Inc and Newamsterdam Pharma Company, together worth $406 billion.
$910 billion Assets Under Management (AUM)
As of 5th August 2024, Bain Capital Life Sciences Investors’s top holding is 2,697,267 shares of Nuvalent Inc currently worth over $205 billion and making up 22.5% of the portfolio value.
In addition, the fund holds 10,473,913 shares of Newamsterdam Pharma Company worth $201 billion.
The third-largest holding is Disc Medicine Inc worth $80.9 billion and the next is Dianthus Therapeutics Inc worth $78 billion, with 3,013,423 shares owned.
Currently, Bain Capital Life Sciences Investors's portfolio is worth at least $910 billion. The total portfolio value may be much higher due to cash
assets that are not publicly disclosed such as fixed income, real estate, or cash equivalents.
Careers at Bain Capital Life Sciences Investors
The Bain Capital Life Sciences Investors office and employees reside in Boston, Massachusetts. According to the last 13-F report filed with the SEC, Adam Koppel serves as the Partner of Bain Capital Life Sciences Investors, LLC at Bain Capital Life Sciences Investors.
Recent trades
In the most recent 13F filing, Bain Capital Life Sciences Investors revealed that it had opened a new position in
Century Therapeutics Inc and bought 5,410,361 shares worth $13.8 billion.
The investment fund also strengthened its position in Disc Medicine Inc by buying
478,522 additional shares.
This makes their stake in Disc Medicine Inc total 1,795,735 shares worth $80.9 billion.
On the other hand, there are companies that Bain Capital Life Sciences Investors is getting rid of from its portfolio.
Bain Capital Life Sciences Investors closed its position in Madrigal Pharmaceuticals Inc on 12th August 2024.
It sold the previously owned 196,995 shares for $52.6 billion.
Adam Koppel also disclosed a decreased stake in Annexon Inc by approximately 0.1%.
This leaves the value of the investment at $41.4 billion and 8,449,208 shares.
One of the average hedge funds
The two most similar investment funds to Bain Capital Life Sciences Investors are Estate Counselors and Oribel Capital Management, L.P.. They manage $910 billion and $910 billion respectively.
Adam Koppel investment strategy
Bain Capital Life Sciences Investors’s portfolio is diversified across 2 sectors.
Currently, their heaviest sector is Health Care — making up 17.8% of
the total portfolio value.
The fund focuses on investments in the United States as
45.8% of the portfolio companies
are based in the United States.
The majority of the companies in the fund’s portfolio are small-cap stocks.
Stocks with a size of more than $100 million in market cap make up
8% of the total holdings value.
On the other hand, large-cap stocks make up only approximately 0.1% of the portfolio.
The average market cap of the portfolio companies is close to $410 million.
The complete list of Bain Capital Life Sciences Investors trades based on 13F SEC filings
These positions were updated on August 12th based on the fund’s latest 13F filing. Quickly find out what the most recently closed or increased positions are.
| Security | Shares Owned | Value | Allocation |
|---|---|---|---|
| Nuvalent Inc |
No change
2,697,267
|
$204,614,675,000 | 22.49% |
| Newamsterdam Pharma Company |
No change
10,473,913
|
$201,203,869,000 | 22.11% |
| Disc Medicine Inc |
36.33%
1,795,735
|
$80,933,776,000 | 8.89% |
| Dianthus Therapeutics Inc |
0.72%
3,013,423
|
$77,987,387,000 | 8.57% |
| Pharvaris N V |
No change
3,303,381
|
$62,103,563,000 | 6.82% |
| Savara Inc |
No change
14,565,457
|
$58,698,792,000 | 6.45% |
| Madrigal Pharmaceuticals Inc |
Closed
196,995
|
$52,605,545,000 | |
| Annexon Inc |
2.92%
8,449,208
|
$41,401,119,000 | 4.55% |
| Kyverna Therapeutics Inc |
6.46%
3,368,370
|
$25,262,775,000 | 2.78% |
| Tango Therapeutics Inc |
No change
2,892,663
|
$24,819,049,000 | 2.73% |
| Solid Biosciences Inc |
No change
4,034,582
|
$22,876,080,000 | 2.51% |
| Mersana Therapeutics Inc |
No change
8,663,673
|
$17,413,983,000 | 1.91% |
| Nurix Therapeutics, Inc. |
Closed
1,132,397
|
$16,646,236,000 | |
| Syros Pharmaceuticals Inc. |
No change
2,749,808
|
$14,189,009,000 | 1.56% |
| Century Therapeutics Inc |
Opened
5,410,361
|
$13,796,421,000 | 1.52% |
| Cabaletta Bio Inc |
2.02%
1,649,964
|
$12,341,731,000 | 1.36% |
| X4 Pharmaceuticals, Inc. |
No change
16,915,784
|
$9,811,155,000 | 1.08% |
| Arcutis Biotherapeutics Inc |
48.76%
1,030,703
|
$9,585,538,000 | 1.05% |
| Atea Pharmaceuticals, Inc. |
No change
2,485,638
|
$8,227,462,000 | 0.90% |
| Rapid Micro Biosystems Inc |
No change
8,434,560
|
$5,566,810,000 | 0.61% |
| C4 Therapeutics, Inc. |
2.65%
1,111,910
|
$5,137,024,000 | 0.56% |
| Nautilus Biotechnology Inc |
No change
2,000,000
|
$4,680,000,000 | 0.51% |
| Xilio Therapeutics Inc |
34.93%
3,785,450
|
$3,586,714,000 | 0.39% |
| Marinus Pharmaceuticals Inc |
62.75%
2,267,680
|
$2,653,186,000 | 0.29% |
| Invivyd Inc |
No change
1,799,595
|
$1,979,555,000 | 0.22% |
| Aclaris Therapeutics Inc |
66.67%
1,000,000
|
$1,100,000,000 | 0.12% |
| No transactions found | |||
| Showing first 500 out of 26 holdings | |||
Hedge funds similar to Bain Capital Life Sciences Investors
- Mount Yale Investment Advisors
- Crescent Grove Advisors
- Ironvine Capital Partners
- Gds Wealth Management
- Advisor Os
- Oribel Capital Management, L.P.
- Estate Counselors
- Jlf Asset Management
- Inspire Investing
- Progeny 3
- Quent Capital
- Caption Management
- 683 Capital Management
- Kontiki Capital Management (hk)